ClinicalTrials.gg

Program

ABBV-1758

A development code.

In AbbVie's pipeline, Pyroglutamate (3pE) Aβ. Its studies are mostly in Alzheimer Disease, led by AbbVie.

Furthest: phase 2, since May 15, 20261 company-led study, 1 open or runningNext primary completion: Oct 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie11 open or runningphase 2since May 15, 2026May 15, 2026Oct 2030phase 2 · NCT07599670
  • Named in AbbVie’s own pipeline as ABBV-1758, phase 1, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 15, 2026First study: phase 2 study in Alzheimer DiseaseFirst studyNCT07599670 · 210 planned · United States, China

Ahead

  1. Oct 2030Primary completion: phase 2 study in Alzheimer DiseaseNCT07599670

TargetBeta

“Pyroglutamate (3pE) Aβ”the company's pipeline, read by Claude · source

Other programs on APP

ProgramCompanyFurthest phaseStudies
donanemabruleEli Lillyphase 414
ALIA-1758AbbViephase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07599670Alzheimer Disease · United States, China2RecruitingOct 2030210

How it is read

Names in the registry

  • “ABBV-1758”, 2 entries

Codes read as this program: ABBV1758.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.